Athersys still looking for funders of stem cell study for stroke patients
CLEVELAND, Ohio — Athersys Inc. continued enrollments in safety and efficacy trials of its adult stem cell therapy, MultiStem, for heart attack patients and those who run the risk of rejecting bone marrow transplants during the third quarter. At the same time, the clinical-stage biopharmaceutical company looked for money for a third trial involving stroke patients. “We believe MultiStem …
[Read the full article here]Related News:
Athersys finishes enrolling heart attack patients for stem cell therapy study
Athersys finishes enrolling heart attack patients for stem cell …
CYT107 Promotes T-Cell Recovery After T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation